AbbVie Inc. · News & developments
AbbVie Expands Skyrizi in Crohn’s Disease
Source: Yahoo FinanceBullish
Yahoo Finance reports on whether AbbVie is undervalued as it expands Skyrizi in Crohn’s disease. The headline identifies the indication expansion but does not provide approval status, sales figures or incremental guidance.
Why this matters
Expansion of Skyrizi into Crohn’s disease could support the product’s post-Humira growth runway and reduce concentration in existing indications. The effect on fair value depends on uptake, reimbursement, competition and whether incremental sales carry the company’s existing margins.